1 completed, 1 recruiting, 1 unknown. 2 Phase 4, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Recruiting 1, Unknown 1 |
| Phase 3 | 1 | Completed 1 |
Follow J.P.S Henriques: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prasugrel Monotherapy Reduced Dose in Acute and Chronic Coronary Syndrome Patients After Percutaneous Coronary Intervention (PROMOTE) Prasugrel 5 mg, Dual Antiplatelet (DAPT) Therapy - Coronary Arterial Disease (CAD), Percutaneous Coronary Intervention (PCI) | Phase 4 | Recruiting | J.P.S Henriques | 300 | 2025-11-13 | 2026-03-04 |
| Rivaroxaban Monotherapy After CYP2C19 Genotype Testing in Patients With Atrial Fibrillation and Percutaneous Coronary Intervention Rivaroxaban - Atrial Fibrillation, Coronary Artery Disease | Phase 4 | Unknown | J.P.S Henriques | 50 | 2024-01-01 | 2023-10-26 |
| Reduction of Catheterization Radiation Exposure Pad (sham) radiation absorbing drape (RADPAD®) - Radiation; Exposure Occupational, Coronary Interventions | Phase 3 | Completed | J.P.S Henriques | 766 | 2017-01-16 | 2023-01-31 |
Atrial Fibrillation (1) · Coronary Artery Disease (1)
2'-deoxythymidylyl-(3'-5')-2'-deoxyadenosine (1) · Prasugrel Hydrochloride (1) · Rivaroxaban (1) · Therapeutics (1)
Netherlands (2)